Cerveau Technologies
Manufacturing · Massachusetts, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
201 Burlington Rd S Bldg, Bedford, Massa...Phone Number
(800) 362-2668Website
www.cerveautechnologies.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Cerveau Technologies
Lantheus Cerveau specializes in developing MK-6240, an investigational Tau PET imaging agent designed for early detection of tau tangles in Alzheimer’s disease. The company actively manages the production, supply chain, and data analytics of this novel imaging biomarker, ensuring compliance with stringent quality standards. Their services include technical operations expertise and customer support, targeting academic researchers and pharmaceutical partners. With a robust international manufacturing network, Lantheus aims to accelerate Alzheimer's research and improve patient outcomes.Explore more
Cerveau Technologies Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Cerveau Technologies your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Cerveau Technologies, which may be a good buyer, showed buying intent in Masked Content Topic
Earning: See what the market has to say on Cerveau Technologies recently announced quarterly report
Check if Cerveau Technologies has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Cerveau Technologies has new funding data
Click to see if Cerveau Technologies had a recent Job posting/layoffs
Product Launch: Get notified when Cerveau Technologies launches new products
Check out if Cerveau Technologies is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Cerveau Technologies
Recommended Actions
Reach out to Masked Content who joined Cerveau Technologies as Masked Content
Find more new buyers
Compare Similar Companies to Cerveau Technologies
Compare insights from companies similar to Cerveau Technologies, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Cerveau Technologies is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Cerveau Technologies is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Cerveau Technologies.
Cerveau Technologies Tech Stack
A closer look at the technologies used by Cerveau Technologies
See more technologies
Cerveau Technologies News & Media
Cerveau Technologies Inc. and Prothena Sign Agreement to Provide Novel Tau Imaging Biomarker for Research and Development of Investigational Therapeutics for Neurodegenerative Diseases
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Othair Prothena Limited, a subsidiary of Prothena Corporation plc (Prothena), which will enable Prothena to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseasesCerveau Technologies Inc. and LEXEO Therapeutics, Inc.- Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
BOSTON--(BUSINESS WIRE)--LEXEO - CerveauCerveau Technologies Inc. and Alnylam® Pharmaceuticals Sign Agreement to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Alnylam® Pharmaceuticals (Alnylam), which will enable Alnylam to use Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The collabCerveau Technologies Inc. Signs Agreement with Roche to Provide Novel Tau Imaging Biomarker for Disease Modifier Research
BOSTON--(BUSINESS WIRE)--Cerveau Technologies, Inc. today announced a research collaboration agreement with Roche Products Limited (Roche), on the use of Cerveau’s [F-18]MK-6240, an investigational imaging agent, in Positron Emission Tomography (PET) scans to assess the status and progression of neurofibrillary tangles (NFTs) in the brain. NFTs made up of aggregated tau protein are a hallmark of several neurodegenerative diseases, including Alzheimer’s disease. The collaboration is focused on u
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Cerveau Technologies
Sign Up For FreeTo access detailed company insights
Lantheus Cerveau specializes in developing MK-6240, an investigational Tau PET imaging agent designed for early detection of tau tangles in Alzheimer’s disease. The company actively manages the production, supply chain, and data analytics of this novel imaging biomarker, ensuring compliance with stringent quality standards. Their services include t... Read More
